Cetera Investment Advisers Acquires 3,801 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cetera Investment Advisers raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the second quarter, Holdings Channel reports. The firm owned 217,702 shares of the biopharmaceutical company’s stock after buying an additional 3,801 shares during the quarter. Cetera Investment Advisers’ holdings in Gilead Sciences were worth $14,937,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. SPC Financial Inc. grew its holdings in shares of Gilead Sciences by 18.2% during the 2nd quarter. SPC Financial Inc. now owns 4,980 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 768 shares during the period. HWG Holdings LP purchased a new stake in Gilead Sciences in the second quarter worth $63,000. EP Wealth Advisors LLC raised its holdings in Gilead Sciences by 1.1% in the second quarter. EP Wealth Advisors LLC now owns 47,459 shares of the biopharmaceutical company’s stock worth $3,256,000 after purchasing an additional 527 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in Gilead Sciences by 25.1% during the second quarter. B. Riley Wealth Advisors Inc. now owns 35,674 shares of the biopharmaceutical company’s stock valued at $2,448,000 after buying an additional 7,155 shares during the period. Finally, Quarry LP bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $43,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.5 %

GILD stock opened at $84.59 on Friday. The business’s 50-day moving average price is $79.06 and its 200-day moving average price is $71.93. The stock has a market cap of $105.39 billion, a P/E ratio of 234.97, a PEG ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a $0.77 dividend. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.64%. Gilead Sciences’s payout ratio is 855.56%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Truist Financial upped their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research note on Monday, September 16th. Finally, Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a research note on Monday, July 8th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $82.12.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.